Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.13), $0.10 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $2.77 million versus the consensus estimate of $1.48 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.